Compare iShares Global Tech ETF (IXN) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Tech ETF vs Johnson & Johnson — how do they compare? iShares Global Tech ETF trades at $149.7 (market cap $10.03B), while Johnson & Johnson trades at $261.49 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 61.6× iShares Global Tech ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares Global Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Tech ETF for 47 Days and Johnson & Johnson for 129 Days on average.
| IXN | JNJ | |
|---|---|---|
Market Cap | $10.03B | $618.09B |
Volume | 286,617 | 6,050,983 |
Sector | Sector/Thematic | Health |
52-Week High | $152.94 | $278.43 |
52-Week Low | $95.76 | $186.00 |
Typical Hold Time | 47 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IXN, the iShares Global Tech ETF, trades at $149.84, down 1.52% on the day but near its 52-week high of $151.40, indicating strong momentum. Technical signals are bullish overall, with moving averages supporting an uptrend, while oscillators remain neutral. Recent news highlights the ETF hitting new highs and trading at a high-teens P/E with a compelling long-term EPS growth outlook, though concentration and AI exposure pose risks.
The outlook for IXN is positive, driven by global tech diversification and AI growth opportunities, but investors face risks from portfolio concentration and market volatility. Wall Street sentiment is bullish, with analysts citing valuation compression and earnings potential as key catalysts for further gains.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
